Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 29, 2020

Quest Diagnostics receives FDA EUA for Covid-19 self-collection kit

Quest Diagnostics has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for a self-collection kit for Covid-19.

Quest Diagnostics has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for a self-collection kit for Covid-19.

The kit enables individuals to self-collect a nasal specimen at home by swabbing the front part of the nostril. It can also be used in healthcare settings when determined to be appropriate by a clinician.

The test is also available for children below 18-years-old, which must be used only under adult supervision.

Specimens are shipped overnight through FedEx at room temperature to Quest Diagnostics to be tested for Covid-19.

The company will use its SARS-CoV-2 RT-PCR test, which received EUA in March to analyse these samples.

Quest Diagnostics chairman, CEO and presidentSteve Rusckowski said: “Covid-19 molecular diagnostic testing has been constrained partly by limited supplies of swabs and trained healthcare professionals to do the specimen collection.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

“The self-collection kit enables an individual to self-collect at home and the process is far less invasive and uncomfortable than many traditional methods.”

The company noted that it has already tested specimens using a similar collection method in real-world settings in the drive-thru and other Covid-19 testing sites in the US.

The self-collection test kits will be available to healthcare providers, states and organisations for return-to-work testing programmes.

Quest Diagnostics plans to have approximately a half-million kits available by the end of next month and aims to scale up the production on an ongoing basis.

Quest Diagnostics senior vice-president and chief medical officer Jay Wohlgemuth said: “We plan to use this device with a range of populations, from state-run programmes and employers to healthcare providers and individuals.

“Our scientists at our advanced diagnostics laboratory in San Juan Capistrano, California developed the technology, which has been validated in real-world studies.”

Last month, the company partnered with Centene to expand real-time reverse transcription-polymerase chain reaction (rRT-PCR) Covid-19 testing across the US.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU